Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
TNYA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.39 - $5.32
Previous CloseN/A
Volume1.07M
Average Volume (3M)4.45M
Market Cap
$113.81M
Enterprise Value$101.36M
Total Cash (Recent Filing)$4.32M
Total Debt (Recent Filing)$13.61M
Price to Earnings (P/E)―
Beta3.47
Next Earnings
May 07, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding162,582,640
10 Day Avg. Volume6,539,210
30 Day Avg. Volume4,449,108
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$10.14Price Target Upside1348.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentTNYA published preclinical data from the TN-201 program for the treatment of MYBPC3 hypertrophic cardiomyopathy in Nature, showcasing its potential efficacy.
Financial StabilityTNYA's current proforma cash is modeled at ~$107M, including a recent $48.9M equity raise and an $8M grant, providing a financial runway into 1H26.
Operational PerformanceTNYA reported a decrease in R&D and SG&A expenses, reflecting a positive trend in managing operational costs.
Bears Say
Market ReactionInvestors were left wanting more from this first cut, leading to a negative stock reaction.
Price Target AdjustmentThe net result of the changes is a decrease in the price target from $18 to $6.
Probability Of SuccessA lower probability of success for TN-201 is now estimated at 30% compared to 45% previously.
---
Ownership Overview
30.89% Insiders
11.55% Mutual Funds
26.56% Other Institutional Investors
24.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.39 and its highest was $5.32 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $113.81M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 42 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Mar 10, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.311 by $0.031.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 162,582,640 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.311. Following the earnings report the stock price went up 8%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
---
Tenaya Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.14 (1348.57% Upside)
$10.14 (1348.57% Upside)
Hedge Fund Trend
Decreased
By 7.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $50.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.16%
12-Months-Change
Fundamentals
Return on Equity
-95.69%
Trailing 12-Months
Asset Growth
-27.67%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics (TNYA) is a biotechnology company focused on discovering, developing, and delivering curative therapies for heart disease. The company operates within the biopharmaceutical sector and is committed to advancing a pipeline of novel therapies aimed at addressing the underlying causes of various forms of heart disease through gene therapy, cellular regeneration, and precision medicine approaches.
---
TNYA Stock 12 Month Forecast
Average Price Target
$10.14
▲(1348.57% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering TNYA
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-34.47%
reiterated a buy rating 3 days ago
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -34.47% per trade.
---